Member Info for Brighty1

All coming together here at last. Key messaging includes the fact that ODD will give Avacta seven years of market exclusivity in the US, which as the company says today "is a significant commercial advantage". Good luck, Brighty

I can't see the GFIN share price being 1p for much longer based on the RNS today. Don't forget that Gfin was x 5 the current SP under 12 months ago at over 5p and was over 20p five years years ago. A major re-rate in the GFIN share price looks to be about to happen. The company is also guiding on month on month profitability moving forward, so for the patient investor the Gfin share price could be much much higher next year. Right sector. Right time etc. Good luck, Brighty

Yes, the numbers are shattering all previous records all the time for the F1 Esports series. Last year they had 494,000 drivers attempting to qualify for the F1 Esports Series (an increase of 108% from the previous year). The full 2021 series achieved over 23 million views across digital platforms, a 103% year on year increase. This is a huge growth sector with regular F1 Esports coverage broadcast from the Gfinity Arena on the official Formula 1 YouTube, Facebook, Twitch, and Huya channels. "Drive to Survive" on Netflix has created a further massive interest in Formula 1 further boosting F1 Esports as a result. It's just going to get bigger and bigger. Not surprising that Gfin says it expects to return month on month profitability moving forward. The share price won't be 1p for much longer. Gfin was x 5 the current SP under 12 months ago at over 5p and as many on here know Gfin was over 20p five years years ago. The opportunities for a major re-rate in the GFIN share price back to previous levels looks compelling. Good luck, Brighty

Exactly right and some on here will recall that when the permit approval for the Utah field test was announced back in July 2019 the TOM share price rose to 6p+ (x 10 our current share price) - yes 6p - and that was based on "hope". Things have progressed nicely to the tipping point where hope and speculation are becoming a reality. If this pans out as we anticipate don't rule out a share price back up to where we were in July 2019. That is approx x 10 where we are today. Good luck all TOM investors, Brighty

Yes, SRA 737 should get the same fast track backing from GSK now. They know that SRA737 (or GSK737 hopefully soon) is a future blockbuster drug in combo with Eli Lilly's Gemcitabine, Merck’s Keytruda and Astra Zeneca's WEE1. I am expecting GSK to accelerate the pace of trialing 737. We all know on here that GSK have got a winner with 737.
Good luck, Brighty

Another excellent piece of commercial news today from the company. Big pharma will be watching what’s going on here and at some stage a takeover will surely be on the cards. Good luck, Brighty

Another major milestone for TXP today, which should see us back to over 175p a share this year. Excellent news. Good luck, Brighty

Good points Nissangtr786 and obviously confirmation of NHS procurement will propel the GDR share price significantly and provide credibility within the sector. The comments from the NICE report on March 29th were most encouraging for GDR and its future prospects. i.e. just how BIG this little company could be globally. Don't forget that a couple of years ago the GDR share price was nearly x 10 the current SP based on hope. Fast forward 2 years and GDR now has something that the NHS is seriously contemplating rolling out. What price do you put on a product that could be sold globally or licenced by a major pharma or even bought out by a major pharma? Good luck, Brighty

The link below articulates for any newbies or prospective investors why the share price of TOM could go stratospheric and seriously multibag. I'm still of the opinion that TOM could be 10p by the end of 2022. There is risk with this share but if it pans out there's serious share price gains to be made.

https://www.proactiveinvestors.co.uk/companies/news/976834/a-year-to-transform-tomco-976834.html

Good luck, Brighty

Totally agree. Significant awareness of MGC being created in the R & D depts and boardrooms of big pharmaceutical companies with all the recent encouraging RNS news coming from the company. No doubt about it that big pharma will be watching MGC. Lets just hope MGC don't get bought out on the cheap. Good luck, Brighty

I'm with you TopCatz on the 40p - 50p soon post, with news on Microsalt and Guident due and then it's £1+ a share moving forward. What we do need more of though if effective editorial articles about TEK in publications such as the Sunday Times, Telegraph, Financial Times, Daily Mail, Wall Street Journal and the trade press etc. It's time more investors heard and read about TEK. i.e. we need more exposure than Cliff's favourite Investors Chronicle to turbo charge the share price to where it really should be now, which is much much higher than at present. Good luck, Brighty

Yes and we should also witness the positive impact of the acquisitions of Megit and Siege moving forward. It’s also worth pointing out that GFIN is guiding the market that it expects month on month profitability from 2023. Plus, at some stage the fact that annualised revenue per unique user grew 31% to 23p and that they are targeting annual revenue per user of 30p in the short to medium term and 50p in the longer term will have a material healthy result on the bottom line. I can see this hitting 5p a share this year and doubling to 10p+ in 2023. Good luck, Brighty

Been here since the 6p days and fully expect to see 60p soon and over £1 in due course. Another great day for TEK investors. Good luck, Brighty

At last! By securing the environmental approvals for Cascadura we can start our re-rate back to 175p and much higher as revenues and profit sky rocket. An excellent day for all those that held and had the faith. Good luck, Brighty

First rate research and observation from Adieuk32 regarding the potential tipping point for TLW investors. You are totally right about clearing the bonds and saving $180 million in interest per year. This would be exceptional news for shareholders moving forward. TLW looks to be getting its house in order ahead of the merger. Last week's Beebei-Potaro announcement was part of the process. i.e. ensuring any negatives are out of the way before the deal is closed. The Kenya deal will be the turning point for TLW. No bonds, no interest and an enlarged business = a much higher share price. Not long to wait now. Good luck, Brighty

Yes, but a x 10 “bagger” only values N4P at £50 million. We operate in a multi billion takeover sector and if Nigel Theobald and the team at N4P get this right we will be valued accordingly at very much more than £50 million. Why? In May GSK announced it had acquired clinical-stage bio company Affinvax for $2.1 billion upfront and up to $1.2 billion in potential development milestones. Yes, 2.1 Billion! The previous month GSK announced it was buying late stage small pharma, Sierra Oncology, for $1.9 billion. Pfizer has recently announced the $11.6 billion deal for Biohaven. i.e. The massive amounts of money being made by the global pharma sector currently will trickle down to acquire much smaller breakthrough businesses such as N4P. I would suggest that x 10 bagger at £50 Million is peanuts for N4P when you focus on the humongous amounts of cash being paid by major pharma co's. N4P is in the right space at the right time. It’s a waiting game, as with some of the other pharma stocks over the last few years. Good luck, Brighty

Yes and make no mistake about it the data issued today is going to generate considerable interest in the boardrooms of the major pharmaceutical companies. It's early days but MGC is likely to be a takeover target. The next logical step is probably a licencing deal. Good luck, Brighty

Big news coming from the company today regarding clinical trials of ArtemiC for Long Covid. When investors cotton on to what MGC is up to the share price will really start to move.

Highlights:

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "The results of this trial represent a real breakthrough for the Company, and are another step forward in demonstrating the ArtemiC range of product's efficacy in treating patients suffering from both COVID-19 and Long COVID.

In a Phase II double-blind, placebo-controlled Clinical Trial on patients with COVID-19, ArtemiC demonstrated the following advantages:

· A full safety and efficacy profile with no drug-adverse events

· The ability to prevent deterioration of COVID-19 patients and achieve faster clinical improvement

· The ability to assist in reducing the pressure on the medical system and support coping with hospitalised patients

· The ability to reduce symptoms and pain associated with COVID-19

· The versatility to be used in community setting as well as in hospitals

This is going to create huge awareness of MGC in the boardrooms of the global major pharmaceutical companies. It's just a matter of time before a takeover or licencing deal happens here.

Good luck, Brighty

Yet more news from MGC today via RNS on the progress of CimetrA. I'm expecting the market to wake up to what is happening soon with MGC. The initial trial results are out in the next few weeks....

* MGC Pharma has received Study approvals and an Import Permit from the South African Health Products Regulatory Authority for MGC Pharma's Phase IIb CimetrA™ dose finding study on patients diagnosed with COVID-19.

CEO: "Clinical trials to date have demonstrated the efficacy of CimetrA™ against COVID-19, so it is crucial that we are able to complete the dosage trials in Israel and now South Africa as quickly as possible so we can move to the next stage of the clinical pipeline and treat those suffering from the effects of the cytokine storm and "Long COVID" more effectively."

* Recent studies of CimetrA™ have indicated the mechanism of the drug could be effective in treating other conditions where a primary factor is inflammation. These include autoimmune diseases Irritable Bowel Disease, Rheumatoid arthritis, Influenza, and dermatological diseases, amongst others.

* The establishment of the South African trial site will help to accelerate completion of the ongoing study, and the collection of data necessary for the submission of CimetrA™ with regulators internationally, which the Company views as a priority, particularly at a time when cases of COVID-19 are once again on the rise.

* The Trial will incorporate key parameters, which include determining the most effective dosage of the treatment, a full safety and Pharmacovigilance profile, and an extensive Pharmacokinetic profile of CimetrA™ to outline the registration and administrative process for approval for sale and use. The Trial will further examine the anti-inflammatory and immune-modulatory effects of CimetrA™ through Cytokine level monitoring. The study to be undertaken in South Africa is an extension of the dosing study currently underway in Israel (See announcement 2 November 2021), with interim analysis results due in the coming weeks.

Exciting times for MGC investors in the coming weeks.

Good luck, Brighty

Yes, we are surely due news soon and don't forget that 3 of the most recent announcements from GDR have NOT been at 7am, they've been INTRADAY at 10am on 29th March (NICE), 3.16pm on 21st March (Paloh study) and at 2pm on 18th March (NHS AIHL).
Good luck, Brighty